IMCR

Immunocore Holdings Ltd

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings Ltd (IMCR) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C
Factor Score 2.3 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 360.0
Rev Growth YoY 13.6%
Gross Margin 32.3%
Price Return 3M 16.5%
Price Return 12M 0.8%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 4.1
ROE -7.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C (2.3) C+ (2.6) C (2.2) C (2.4) C- (1.9) C (2.3)
2026-08-04 C (2.3) C+ (2.6) C (2.2) C (2.4) C- (1.9) C (2.3)
2026-08-03 C (2.3) C+ (2.5) C+ (2.6) C (2.4) C- (2.0) C (2.4)
2026-08-02 C (2.3) C+ (2.5) C+ (2.6) C (2.4) C- (1.9) C (2.4)
2026-07-29 C+ (2.6) B (3.4) B (3.3) C (2.4) D+ (1.5) C+ (2.7)
Page 1 of 3